Overview

Radiotherapy Market Introduction

The global radiotherapy market is forecasted to value over USD 7 billion by 2026 end and register a CAGR of over 4% from the forecast period 2019-2026.Improvements and further amendments in image-guided radiotherapy are propelling the market. The rising preference towards radiotherapy procedures for cancer treatment coupled with increasing usage of particle therapy for cancer diagnosis is spurring the market growth. Latest technological advancements in radiotherapy are expected to propel the market. Furthermore, rising incidences of cancer have expanded the market. According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. The rise in research and development activities regarding cancer treatment launched by non-government and government organizations is expected to boost the market. 

Radiotherapy Market Overview

The market is classified into product type, type, application, end-user, and region. In terms of type, the market is segmented into radiotherapy, internal beam radiotherapy, systemic radiotherapy, and external beam radiotherapy. External beam radiotherapy is expected to achieve high growth owing to the latest advancements in particle beam therapy. Growing research activities related to the field of radiation oncology is expected to propel the market.

Based on product type, external beam radiotherapy is expected to achieve the highest growth owing to the affordable cost of equipment of linear accelerator. The 360-degree radiation treatment offered by tomotherapy is adding further growth opportunities thus spurring the market.

Based on application, the prostate cancer segment of external beam radiotherapy market holds a vast share of the market. The rising cases of prostate cancer coupled with high success rates of external beam radiotherapy are expected to escalate the market. Moreover, the minimum long term risks associated with external beam radiotherapy is expected to positively influence the market.

On the basis of end-user, hospital segment is expected to hold the major market share. Rising healthcare infrastructure and easy access and availability of advanced equipment have expanded the market. The rising cases of cancer globally has resulted in more deployment of hospitals, thus accelerating the market growth. 

Based on regions, North America dictates the market growth. Presence of prominent players and developed healthcare infrastructure is boosting the market in the region. Growing cases of cancer and favorable government policies are promoting adoption of radiotherapy, thus positively influencing the market. 

 Asia-Pacific region is expected to be a lucrative region for manufacturers owing to a rapidly improving healthcare infrastructure and growing per capita income in emerging economies like China, Japan and India. In addition, favorable policies launched by the governments of these countries is expected to strengthen market position in the region.  

Major players of the market are Hitachi Ltd., IsoRay Medical, Inc, Ion Beam Applications SA, Provision Healthcare, Varian Medical Systems, Inc, Mevion Medical Systems, Inc, Panacea Medical Technologies Pvt.Ltd, Accuray Incorporated and Elekta AB. 

Competitive Landscape: 
●     Varian Medical Systems in 2017, opened its centre in Jundiai, Brazil. The move will increase the access to advanced radiotherapy equipment and treatment across Brazil
●     Varian Medical Systems launched an innovative treatment platform called Halcyon Treatment System. The system eases treatment delivery with increased speed and high-quality plans
●     Mitsubishi Electric in 2017 decided to transfer its particle therapy systems to Hitachi
 
Radiotherapy Market Segmentation 

By Product Type 
●    External Beam Radiotherapy 
▪      Linear Accelerators
▪      Particle Therapy System
▪      Conventional Cobalt-60 Teletherapy Units                 
                    
●    Internal Beam Radiotherapy/Brachytherapy 
▪      Seeds
▪      Applicators
▪      Afterloaders
▪      Electronic Brachytherapy Products
                    
●    Systemic Radiotherapy 
▪      Iobenguane (I-131)
▪      Samarium-153
▪      Rhenium-186
                     
By Type 
●    External Beam Radiotherapy 
▪      Image-Guided Radiotherapy
▪      3d Conformal Radiotherapy
▪      Intensity-Modulated Radiotherapy
▪      Stereotactic Therapy
▪      Particle Therapy
                             
●    Internal Beam Radiotherapy 
▪      Low-Dose-Rate Brachytherapy      
▪      High-Dose-Rate Brachytherapy                 
▪      Pulsed-Dose-Rate Brachytherapy
                    
●    Systemic Radiotherapy 
▪      Intravenous Radiotherapy  
▪      Oral Radiotherapy
▪      Instillation Radiotherapy
                    
By Application 
●    External Beam Radiation Therapy
▪      Prostate Cancer
▪      Breast Cancer
▪      Lung Cancer
▪      Head and Neck Cancer
▪      Colorectal Cancer
▪      Other Cancers
 
●    Internal Beam Radiotherapy/Brachytherapy 
▪      Prostate Cancer
▪      Gynecological Cancer
▪      Breast Cancer
▪      Cervical Cancer
▪      Penile Cancer
▪      Other Cancers
 
 By End User 
●     Hospital        
●     Independent Radiotherapy Centers
                    
By Region: 
●     North America
●     Europe
●     Asia Pacific
●     Latin America
●     Rest of the World

 

FutureWise Key Takeaways
●  Growth Prospects
●  SWOT Analysis
●  Key Trends
●  Key data-points affecting market growth
 
Objectives of the Study:
• To provide with an exhaustive analysis on radiotherapy the market by type, by product type, by application, by end-user and by region 
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America and rest of the world
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financial and core competencies

Table of Contents

1 Introduction 

    1.1 Objectives of the Study 

    1.2 Market Definition 

    1.3 Market Scope 

           1.3.1 Markets Covered

           1.3.2 Years Considered for the Study

    1.4 Currency 

    1.5 Stakeholders 

 

2 Research Methodology 

    2.1 Research Data 

           2.1.1 Secondary Data

                    2.1.1.1 Key Data From Secondary Sources

           2.1.2 Primary Data

                    2.1.2.1 Key Data From Primary Sources

    2.2 Market Size Estimation 

           2.2.1 Product-Based Market Estimation

           2.2.2 Primary Research Validation

    2.3 Market Breakdown and Data Triangulation 

    2.4 Research Limitations and Assumptions 

           2.4.1 Limitations

           2.4.2 Assumptions

 

3 Executive Summary 

4 Premium Insights 

    4.1 Market Overview 

    4.2 Europe: External Market, By Type, 2018 

    4.3 Internal Beam Radiotherapy/Brachytherapy Market, By Product Type 

    4.4 External Beam Market, By Application 

    4.5 Regional Analysis: Market, By End User 

    4.6 Market, By Country 

 

5 Market Overview 

    5.1 Introduction 

    5.2 Market Dynamics 

           5.2.1 Drivers

                    5.2.1.1 Technological Advancements

                    5.2.1.2 Rising Prevalence of Cancer

                    5.2.1.3 Increasing Number of Conferences and Symposia Focusing on Spreading Awareness About the Benefits of Radiotherapy

                    5.2.1.4 Growing Use of Particle Therapy for Cancer Treatment

           5.2.2 Restraints

                    5.2.2.1 Lack of Adequate Healthcare Infrastructure

                    5.2.2.2 Shortage of Trained Personnel

                    5.2.2.3 Affordability and Accessibility of Treatment

                    5.2.2.4 Complex Nature of Radiotherapy

           5.2.3 Opportunities

                    5.2.3.1 Emerging Markets

                    5.2.3.2 Growing Government and Private Investments to Meet the Increasing Demand for Cancer Treatment

                    5.2.3.3 Improving Reimbursement Scenario

           5.2.4 Challenges

                    5.2.4.1 Difficulties in Visualizing Tumors During Radiotherapy Procedures

                    5.2.4.2 Risk of Radiation Exposure

    5.3 Industry Trends 

           5.3.1 Growing Adoption of Pencil-Beam Scanning

           5.3.2 Growing Number of Collaborations and Acquisitions

 

6  By Product Type 

    6.1 Introduction 

    6.2 External Beam Radiotherapy 

           6.2.1 Linear Accelerators

                    6.2.1.1 Conventional Linear Accelerators

                               6.2.1.1.1 Lower Equipment and Maintenance Cost Will Drive the Market for Conventional Linacs

                    6.2.1.2 Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators

                               6.2.1.2.1 Automation and Real-Time Tracking Features Have Ensured Demand for Stereotactic Advanced Linac

                               6.2.1.2.2 Gamma Knife

                                             6.2.1.2.2.1 The Gamma Knife System is Considered A Gold Standard for Brain Tumor Treatment

                               6.2.1.2.3 Cyberknife

                                             6.2.1.2.3.1 Cyberknife Offers A Precise Radiation Delivery Method With Specialized Tracking and Robotic Correction Capabilities

                               6.2.1.2.4 Tomotherapy

                                             6.2.1.2.4.1 360-Degree (Helical) Radiation Treatment With Tomotherapy is Adding Growth Opportunities to This Segment

           6.2.2 Particle Therapy Systems

                    6.2.2.1 Cyclotrons

                               6.2.2.1.1 Leading Players in the Particle Therapy Market Mainly Manufacture Cyclotrons 

                    6.2.2.2 Synchrotrons

                               6.2.2.2.1 Increasing Investment for the Development of Synchrotron Facilities are Contributing to Market Growth

                    6.2.2.3 Synchrocyclotrons

                               6.2.2.3.1 High Space Requirements of Synchrocyclotrons are Limiting Its Widespread Adoption

           6.2.3 Conventional Cobalt-60 Teletherapy Units

                    6.2.3.1 High Cost and Risk of Radiation Exposure With Cobalt-60 Radioisotopes Have Hindered the Growth of This Segment

    6.3 Internal Beam Radiotherapy/Brachytherapy 

           6.3.1 Seeds

                    6.3.1.1 Adverse Side-Effects Associated With Seeds Limit Their Adoption

           6.3.2 Applicators

                    6.3.2.1 Manual Applicators Pose A High Risk of Radiation Exposure to the Patients and Staff

           6.3.3 Afterloaders

                    6.3.3.1 Modern Afterloaders Offer Proper Positioning and Better Control of Isotopes Inside the Patient Body

           6.3.4 Electronic Brachytherapy Products

                    6.3.4.1 Electronic Brachytherapy Requires Low Amount of Shielding Than Alternatives

    6.4 Systemic Radiotherapy 

           6.4.1 Iobenguane (I-131)

                    6.4.1.1 Increasing Incidence of Thyroid Cancer is Driving the Growth of This Segment

           6.4.2 Samarium-153

                    6.4.2.1 Samarium-153 has Wide Applications for Bone Metastasis

           6.4.3 Rhenium-186

                    6.4.3.1 Lack of Insurance Coverage With the Use of Rhenium-186 Restricting Its Growth

           6.4.4 Other Systemic Radiotherapy Products

 

7 By Type 

    7.1 Introduction 

    7.2 External Beam Radiotherapy 

           7.2.1 Image-Guided Radiotherapy

                    7.2.1.1 Image-Guided Radiotherapy is Widely Used to the Treatment of Deep-Seated Tumors

           7.2.2 3d Conformal Radiotherapy

                    7.2.2.1 Multiple Beams With 3d-Crt Allow Precise Radiation Conforming to the Tumor Size and Shape

           7.2.3 Intensity-Modulated Radiotherapy

                    7.2.3.1 Volumetric Arc Therapy

                               7.2.3.1.1 Advancements in the Vmat Technology Driving Its Widespread Adoption

                    7.2.3.2 Tomotherapy

                               7.2.3.2.1 Minimal Exposure to Normal Tissues – A Major Advantage of Tomotherapy

           7.2.4 Stereotactic Therapy

                    7.2.4.1 Stereotactic Therapy Offers A Minimally Invasive Alternative to Ablation Surgeries

           7.2.5 Particle Therapy

                    7.2.5.1 Particle Therapy is Increasingly Being Adopted as A Primary Mode of Treatment for Various Cancer Types

    7.3 Internal Beam Radiotherapy 

           7.3.1 Low-Dose-Rate Brachytherapy

                    7.3.1.1 Lower Risk of Radiation Exposure to the Surrounding Tissues With Ldr Supporting Market Growth

           7.3.2 High-Dose-Rate Brachytherapy

                    7.3.2.1 Better Patient Care With HDR is Driving Its Widespread Adoption

           7.3.3 Pulsed-Dose-Rate Brachytherapy

                    7.3.3.1 Pulsed-Dose Rate Brachytherapy Combines the Advantages of HDR and Ldr Brachytherapy

    7.4 Systemic Radiotherapy 

           7.4.1 Intravenous Radiotherapy

                    7.4.1.1 Intravenous Route of Brachytherapy Results in Maximum Bioavailability

           7.4.2 Oral Radiotherapy

                    7.4.2.1 Longer Distribution Time Associated With the Oral Mode of Radiation Delivery Limiting Its Demand

           7.4.3 Instillation Radiotherapy

                    7.4.3.1 Lesser Localization With Instillation Brachytherapy is Limiting Its Widespread Adoption

 

8  By Application 

    8.1 Introduction 

    8.2 External Beam Radiation Therapy 

           8.2.1 Prostate Cancer

                    8.2.1.1 High Incidence of Prostate Cancer Will Drive the Demand for Ebrt

           8.2.2 Breast Cancer

                    8.2.2.1 Adoption of Advanced Ebrt Systems and Increasing Research Will Drive Market Growth

           8.2.3 Lung Cancer

                    8.2.3.1 Radiotherapy Can Be Used as Solo Or Combination Therapy for Lung Cancer

           8.2.4 Head and Neck Cancer

                    8.2.4.1 Benefits of External Radiotherapy Will Support Its Use in Head and Neck Cancer Treatment

           8.2.5 Colorectal Cancer

                    8.2.5.1 Availability of Alternative Therapeutic Options Limits the Growth of This Segment

           8.2.6 Other Cancers

    8.3 Internal Beam Radiotherapy/Brachytherapy 

           8.3.1 Prostate Cancer

                    8.3.1.1 Rapidity and Precision of Brachytherapy in Prostate Cancer Treatment Have Driven Market Growth

           8.3.2 Gynecological Cancer

                    8.3.2.1 Availability of Alternatives Hinders the Adoption of Brachytherapy in Gynecological Cancer Treatment

           8.3.3 Breast Cancer

                    8.3.3.1 Precision and Rapid Treatment Times are Driving the Use of Brachytherapy in Breast Cancer Applications

           8.3.4 Cervical Cancer

                    8.3.4.1 A Combination of Brachytherapy and Chemotherapy is Typically Used for Cervical Cancer Treatment

           8.3.5 Penile Cancer

                    8.3.5.1 Advantages of Brachytherapy in Penile Cancer Treatment Have Driven Its Adoption

           8.3.6 Other Cancers

 

9  By End User 

    9.1 Introduction 

           9.1.1 Hospitals

                    9.1.1.1 Increasing Number of Small-Footprint Advanced Radiotherapy Products Promoting Their Adoption in Hospitals

           9.1.2 Independent Radiotherapy Centers

                    9.1.2.1 Rising Consolidation of Healthcare Networks is Challenging the Growth of Freestanding Radiotherapy Centers

 

10  By Region 

     10.1 Introduction 

     10.2 North America 

             10.2.1 US

                        10.2.1.1 Growing Government Initiatives Boosting the Adoption of Radiotherapy in the Us

             10.2.2 Canada

                        10.2.2.1 Rising Cancer Incidence Driving the Demand for Radiotherapy in Canada

     10.3 Europe 

             10.3.1 Germany

                        10.3.1.1 Increasing Awareness of Novel and Advanced Radiotherapy Products A Key Factor Contributing to Market Growth

             10.3.2 France

                        10.3.2.1 Growing Government Initiatives Boosting the Adoption of Radiotherapy in France

             10.3.3 UK

                        10.3.3.1 Leading Market Players Focusing on Expanding Their Product Offerings in the Uk

             10.3.4 Rest of Europe

     10.4 Asia Pacific 

             10.4.1 China

                        10.4.1.1 Presence of A Large Number of Local Manufactures Supporting the Growth of the Market in China

             10.4.2 Japan

                        10.4.2.1 Rising Prevalence of Cancer is Driving the Adoption of Radiotherapy in Japan

             10.4.3 India

                        10.4.3.1 Shortage of Skilled Radiotherapy Professionals in India is Restraining Market Growth

             10.4.4 Rest of Asia Pacific

     10.5 Rest of the World 

 

11 Competitive Landscape (Page No. - 173)

     11.1 Introduction 

     11.2 Market Share Analysis 

     11.3 Competitive Scenario 

             11.3.1 Product Launches and Approvals

             11.3.2 Acquisitions

             11.3.3 Expansions

             11.3.4 Partnerships, Agreements, and Collaborations

     11.4 Vendor Dive Overview 

     11.5 Vendor Inclusion Criteria 

     11.6 Vendor Dive 

             11.6.1 Vanguards

             11.6.2 Innovators

             11.6.3 Dynamic Players

             11.6.4 Emerging Companies

 

12 Company Profiles

 (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, FutureWise View)*

     12.1 Accuray Incorporated 

     12.2 C. R. Bard, Inc. 

     12.3 Elekta 

     12.4 Hitachi, Ltd. 

     12.5 IBA (Ion Beam Applications Sa) 

     12.6 Isoray Medical, Inc. 

     12.7 Mevion Medical Systems, Inc. 

     12.8 Optivus Proton Therapy, Inc. 

     12.9 Panacea Medical Technologies Pvt. Ltd. 

     12.10 P-Cure Ltd. 

     12.11 Provision Healthcare, LLC. 

     12.12 Sumitomo Heavy Industries, Ltd 

     12.13 Theragenics Corporation 

     12.14 Varian Medical Systems, Inc. 

     12.15 Viewray Inc. 

*Details on FutureWise View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

 

Tables

Figures